Off-Pump Bypass Benefits To Be Evaluated Further At Five Years – Study
This article was originally published in The Gray Sheet
Executive SummaryBypass surgery on a beating heart significantly lowers in-hospital morbidity without compromising outcomes at one to three years when compared with conventional stopped-heart surgery, two recent studies suggest
You may also be interested in...
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.